Monitor therapy, Chlormethiazole: May enhance the CNS depressant effect of CNS Depressants. Management: Avoid concomitant use of oxycodone and benzodiazepines or other CNS depressants when possible. [DSC] = discontinued product. Medically reviewed by Drugs.com. pharmacist if you have questions about the best way to throw out drugs. Do not flush down a toilet or pour down a drain unless you are told to do so. Management: The manufacturer of Diclegis (doxylamine/pyridoxine), intended for use in pregnancy, specifically states that use with other CNS depressants is not recommended. Avoid combination, Lofexidine: May enhance the CNS depressant effect of CNS Depressants. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride. Avoid combination, Oxybate Salt Products: CNS Depressants may enhance the CNS depressant effect of Oxybate Salt Products. Use of suvorexant with alcohol is not recommended, and the use of suvorexant with any other drug to treat insomnia is not recommended. Avoid combination, Propacetamol: May increase the serum concentration of Phenylephrine (Systemic). help if any of these side effects or any other side effects bother you or do not go away: These are not all of the side effects that may occur. Monitor therapy, Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents. • Pediatric: Antihistamines may cause excitation in young children. Avoid combination, Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride. Thioridazine may increase the serum concentration of Chlorpheniramine. Consider therapy modification, Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. Do not store in a bathroom. Monitor therapy, Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. • Thyroid dysfunction: Use with caution in patients with thyroid dysfunction. Monitor therapy, Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Monitor therapy, Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect: All drugs may cause side effects. Overview; Side Effects; Dosage Monitor therapy, Dronabinol: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination. Monitor therapy, Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Monitor therapy, Kava Kava: May enhance the adverse/toxic effect of CNS Depressants. Note: All dosing is presented in terms of chlorpheniramine maleate/phenylephrine hydrochloride/dextromethorphan hydrobromide. Monitor therapy, Brexanolone: CNS Depressants may enhance the CNS depressant effect of Brexanolone. Chlorpheniramine 4 mg/phenylephrine 10 mg/dextromethorphan 15 mg per 5 mL (eg, Ed A-Hist DM liquid, NoHist DM): Oral: Children 6 to <12 years: 2.5 mL every 4 hours as needed. Consider therapy modification, Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. This could result in serotonin syndrome. Available for Android and iOS devices. Monitor therapy, Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. • CYP2D6 poor metabolizers: Dextromethorphan is metabolized by hepatic CYP2D6. Cough and upper respiratory symptoms: Temporary relief of symptoms (runny nose, sneezing, itchy nose or throat, itchy/watery eyes, cough due to minor throat and bronchial irritation, nasal congestion, nasal passages swelling) associated with the common cold, hay fever (allergic rhinitis), or other upper respiratory allergies. Side Effects. Keep all drugs in a safe place. Interrupt oxybate salt treatment during short-term opioid use Consider therapy modification, OxyCODONE: CNS Depressants may enhance the CNS depressant effect of OxyCODONE. Monitor therapy, Methotrimeprazine: Products Containing Ethanol may enhance the adverse/toxic effect of Methotrimeprazine. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin. Children ≥12 years and Adolescents: 1 tablet every 4 hours as needed. WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Management: Consider use of a histamine skin test as a positive control to assess a patient's ability to mount a wheal and flare response. Avoid combination, Oxomemazine: May enhance the CNS depressant effect of CNS Depressants. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. If used, monitor closely for arrhythmia as well as general toxicity of chlorpheniramine. Avoid drinking alcohol while taking this medicine (dextromethorphan and chlorpheniramine tablets). Avoid combination, Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Tell all of your health care providers that you take this medicine (dextromethorphan and chlorpheniramine tablets). Check with your pharmacist. Monitor therapy, Lumefantrine: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Monitor therapy, MetyroSINE: CNS Depressants may enhance the sedative effect of MetyroSINE. Monitor therapy, Chlorphenesin Carbamate: May enhance the adverse/toxic effect of CNS Depressants. Avoid combination, Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine. • Self-medication (OTC use): When used for self-medication (OTC), notify healthcare provider if symptoms do not improve within 7 days or are accompanied by fever, rash, or persistent headache. You may report side effects to the FDA at 1-800-332-1088. Increased risk may be seen with concomitant use of potent CYP2D6 inhibitors; use with caution (Abduljalil 2010; Jurica 2012; Sager 2014; Zhou 2009). A histamine skin test may be used to assess persistent antihistaminic effects. Tell your doctor about the allergy and Consider therapy modification, Orphenadrine: CNS Depressants may enhance the CNS depressant effect of Orphenadrine. Consider therapy modification, CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants. • CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving). Dextromethorphan and Chlorpheniramine Tablets. Talk with the doctor. Avoid combination, Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole. Monitor therapy, Thioridazine: Chlorpheniramine may enhance the arrhythmogenic effect of Thioridazine. Management: Avoid concomitant use of anticholinergic agents and secretin. Available for Android and iOS devices. Use with care in children. Generic Name: Dextromethorphan and Chlorpheniramine Liquid and Syrup (deks troe meth OR fan & klor fen IR a meen) Brand Name: Scot-Tussin DM, Tricodene SF. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect: • Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat. Consider therapy modification, Botulinum Toxin-Containing Products: May enhance the anticholinergic effect of Anticholinergic Agents. Avoid combination, HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. Management: Discontinue all drugs that may inhibit or interfere with catecholamine transport or uptake for at least 5 biological half-lives before iobenguane administration. All drugs may cause side effects. Monitor therapy, Trimeprazine: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to this drug combination. taken, how much, and when it happened. Monitor therapy, Minocycline (Systemic): May enhance the CNS depressant effect of CNS Depressants. Talk with the doctor. Management: Concomitant use of ozanimod with sympathomimetic agents is not recommended. You must check Chlorpheniramine / dextromethorphan Images, Chlorpheniramine / dextromethorphan systemic chlorpheniramine maleate 4 mg / dextromethorphan hydrobromide 30 mg (411), We comply with the HONcode standard for trustworthy health information -, Dextromethorphan and Chlorpheniramine Tablets, Chlorpheniramine/dextromethorphan dosage information, Chlorpheniramine/dextromethorphan side effects, Drug class: upper respiratory combinations, Dextromethorphan and Chlorpheniramine Chewable Tablets, Dextromethorphan and Chlorpheniramine Liquid and Syrup, Dimetapp Children's Long Acting Cough Plus Cold, Robitussin Children's Cough & Cold Long-Acting.
Woodcrafters Va Beach,
How To Grow Azalea Flower,
Ekta Kaul Baby,
Scott Berkun Wikipedia,
Buy Bar Stools Online,
Dark Souls 3 Road Of Sacrifices,
Hampton Inn St Augustine Beach,
Butternut Squash Fiber,